Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J O'Callaghan

Showing results (581-590 of 601) with videos related to

Pageof 61
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2016
Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal CancerGeoffrey Liu, Dongsheng Tu, Marcia Lewis, et al.
JAMA Oncology|May 8, 2020
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 StudyEric X Chen, Derek J Jonker, Jonathan M Loree, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2013
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 TrialLillian L Siu, Jeremy D Shapiro, Derek J Jonker, et al.
Journal of the National Cancer Institute|January 29, 2026
Effects of a structured exercise program on motivational outcomes in patients with Colon cancerKerry S Courneya, Christopher M Booth, Janette L Vardy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2013
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17Christos S Karapetis, Derek Jonker, Manijeh Daneshmand, et al.
The Lancet. Oncology|September 8, 2024
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 studyLaura A Dawson, Jolie Ringash, Alysa Fairchild, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II TrialNick Pavlakis, Katrin M Sjoquist, Andrew J Martin, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 20, 2016
Effects of a Structured Exercise Program on Physical Activity and Fitness in Colon Cancer Survivors: One Year Feasibility Results from the CHALLENGE TrialKerry S Courneya, Janette L Vardy, Christopher J O'Callaghan, et al.
Nature Communications|August 26, 2022
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinomaDaniel J Renouf, Jonathan M Loree, Jennifer J Knox, et al.
Nature Communications|March 7, 2026
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinomaDaniel J Renouf, James T Topham, Jonathan M Loree, et al.
Pageof 61

Showing results (581-590 of 601) with videos related to

Sort By:
Pageof 61
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2016
Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal CancerGeoffrey Liu, Dongsheng Tu, Marcia Lewis, et al.
JAMA Oncology|May 8, 2020
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 StudyEric X Chen, Derek J Jonker, Jonathan M Loree, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2013
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 TrialLillian L Siu, Jeremy D Shapiro, Derek J Jonker, et al.
Journal of the National Cancer Institute|January 29, 2026
Effects of a structured exercise program on motivational outcomes in patients with Colon cancerKerry S Courneya, Christopher M Booth, Janette L Vardy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2013
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17Christos S Karapetis, Derek Jonker, Manijeh Daneshmand, et al.
The Lancet. Oncology|September 8, 2024
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 studyLaura A Dawson, Jolie Ringash, Alysa Fairchild, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II TrialNick Pavlakis, Katrin M Sjoquist, Andrew J Martin, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 20, 2016
Effects of a Structured Exercise Program on Physical Activity and Fitness in Colon Cancer Survivors: One Year Feasibility Results from the CHALLENGE TrialKerry S Courneya, Janette L Vardy, Christopher J O'Callaghan, et al.
Nature Communications|August 26, 2022
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinomaDaniel J Renouf, Jonathan M Loree, Jennifer J Knox, et al.
Nature Communications|March 7, 2026
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinomaDaniel J Renouf, James T Topham, Jonathan M Loree, et al.
Pageof 61